Literature DB >> 7506950

Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood.

M N Dworzak1, G Fritsch, P Buchinger, C Fleischer, D Printz, A Zellner, A Schöllhammer, G Steiner, P F Ambros, H Gadner.   

Abstract

The cell-surface expression of the MIC2 antigen defined by the monoclonal antibody 12E7 was investigated on human leukocytes in bone marrow (BM), thymus, and peripheral blood (PB) using multiparameter flow cytometry and cell sorting. In contrast to preceding reports, we found that the MIC2 antigen is not restricted to T cells and monocytes. We show that it is also expressed in the B cell and in the granulocytic lineage, the levels of expression being related to distinct maturational stages. CD34+ cells of BM were found to express the antigen at high levels. Along the granulocytic maturation pathway from CD34+CD33+ blasts to mature granulocytes, MIC2 densities appeared progressively reduced with a considerable decline at the myelocyte stage. In B lymphopoiesis, the earliest CD34+ CD10+ B-cell precursor (BCP) cells, further subdivided by expression of CD19, displayed the highest MIC2 density of BM leukocytes. All later BCP stages showed lower MIC2 expression levels, with a remarkable reduction concomitant with loss of the CD34 antigen at the CD10+CD20- surface mu-chain- stage, and a subsequent slight upregulation along with maturation to CD10-CD20high surface mu-chain+ BCPs. The brightest MIC2 expression of all cells tested was displayed by the most immature thymic T-lineage cells characterized by the antigenic profile CD34weakor- CD7++ surface CD3-CD1a(weak) CD4weak CD8-or weak. Common thymocytes stained slightly less intense with 12E7, whereas all subsequent stages of T-lineage cells in thymus, PB, or BM showed markedly reduced MIC2 levels. Mature peripheral CD4+ as well as CD8+ T cells displayed a bimodal distribution of MIC2. In the CD4+ population, the distinct MIC2 levels were related to the well-studied functional subdivision by differential expression of CD45 isoforms, the helper-inducer/memory subset showing higher MIC2 expression than helper-suppressor/naive CD4+ T cells. Similarly high MIC2 densities were found on CD16+ natural killer cells and on CD14+ monocytes, whereas mature peripheral B cells exhibited low or intermediate expression, and granulocytes exhibited no or only dim expression. These results document that the MIC2 antigen (1) is expressed on all leukocyte lineages; (2) is differentially expressed during T- and B-lymphoid, as well as granulocytic maturation; (3) shows highest expression in the most immature lymphocytic and granulocytic developmental stages; and (4) is also differentially expressed on functional T-cell subsets. We speculate that these observations imply a functional significance of MIC2 in the network of hematopoietic adhesion pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506950

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

2.  Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens.

Authors:  Sebastian Fernandez-Pol; Matt van de Rijn; Yasodha Natkunam; Gregory W Charville
Journal:  Virchows Arch       Date:  2018-07-17       Impact factor: 4.064

3.  Neonatal hyperimmune T-cell reaction mimicking T-cell non-Hodgkin's lymphoma following BCG and hepatitis B co-vaccination.

Authors:  Snjezana Dotlic; Semir Vranic; Gordana Jakovljevic; Ivana Ilic; Mirjana M Kardum-Paro; Stefan D Dojcinov
Journal:  Virchows Arch       Date:  2012-09-12       Impact factor: 4.064

4.  sdf1 Expression reveals a source of perivascular-derived mesenchymal stem cells in zebrafish.

Authors:  Troy C Lund; Xiaobai Patrinostro; Ashley C Kramer; Paul Stadem; Lee Ann Higgins; Todd W Markowski; Matt S Wroblewski; Diane S Lidke; Jakub Tolar; Bruce R Blazar
Journal:  Stem Cells       Date:  2014-10       Impact factor: 6.277

5.  CD99 acts as an oncosuppressor in osteosarcoma.

Authors:  Maria Cristina Manara; Ghislaine Bernard; Pier-Luigi Lollini; Patrizia Nanni; Monia Zuntini; Lorena Landuzzi; Stefania Benini; Giovanna Lattanzi; Marika Sciandra; Massimo Serra; Mario Paolo Colombo; Alain Bernard; Piero Picci; Katia Scotlandi
Journal:  Mol Biol Cell       Date:  2006-01-18       Impact factor: 4.138

6.  Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection.

Authors:  Mikhail Roshal; Jonathan R Fromm; Stuart Winter; Kimberly Dunsmore; Brent L Wood
Journal:  Cytometry B Clin Cytom       Date:  2010-05       Impact factor: 3.058

7.  Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma.

Authors:  Chang Ohk Sung; Young H Ko; Sanghui Park; Kihyun Kim; Wonseog Kim
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

8.  Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow.

Authors:  Steven G Dubois; C Lorrie Epling; Juli Teague; Katherine K Matthay; Elizabeth Sinclair
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

9.  Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells.

Authors:  H W Sohn; E Y Choi; S H Kim; I S Lee; D H Chung; U A Sung; D H Hwang; S S Cho; B H Jun; J J Jang; J G Chi; S H Park
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.

Authors:  Haydar Çelik; Marika Sciandra; Bess Flashner; Elif Gelmez; Neslihan Kayraklıoğlu; David V Allegakoen; Jeff R Petro; Erin J Conn; Sarah Hour; Jenny Han; Lalehan Oktay; Purushottam B Tiwari; Mutlu Hayran; Brent T Harris; Maria Cristina Manara; Jeffrey A Toretsky; Katia Scotlandi; Aykut Üren
Journal:  Oncogene       Date:  2018-01-31       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.